ArticleNature2026
Acquired genetic and cell-state changes in IDH-mutant glioma progression.
Abstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- IDH-Mutant Diffuse Glioma: From Metabolic Origins to Targeted Therapy.Journal of clinical medicine · 2026Review
- Immunometabolic control of macrophage plasticity in wound healing: mechanistic insights and therapeutic opportunities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
51 authors.
Kevin C Johnson *Department of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-0016-5158
Avishay Spitzer *Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID http://orcid.org/0000-0001-6551-9338
Frederick S Varn *The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.ORCID http://orcid.org/0000-0001-6307-016X
Masashi Nomura *Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6095-7849
Luciano Garofano *Department of Public Health Sciences, Division of Biostatistics, University of Miami, Miller School of Medicine, Miami, FL, USA.ORCID http://orcid.org/0000-0001-8582-0865
Tamrin ChowdhuryDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-6747-6316
Anuja LipsaNORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.ORCID http://orcid.org/0000-0002-9668-6048
Linbin ZhangDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.
Ester Calvo FernándezDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Tanyeri BarakDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.
A Gulhan Ercan-SencicekDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-2838-3341
Ayse Buket PeksenDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.
Kevin J AndersonThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.ORCID http://orcid.org/0000-0002-2362-273X
C Mircea S TesileanuDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-3541-9242
Samirkumar B AminDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-3207-9505
Emre KocakavukDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.
Dacheng ZhaoDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.
Fulvio D'AngeloSylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA.ORCID http://orcid.org/0000-0002-4940-4693
Simona MigliozziSylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA.
Lillian BussemaDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5469-3816
Simon GritschDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Hyo-Eun MoonDepartment of Neurosurgery, Cancer Research Institute, Hypoxia Ischemia Disease Institute, Seoul National University, Seoul, Republic of Korea.
Sun Ha PaekDepartment of Neurosurgery, Cancer Research Institute, Hypoxia Ischemia Disease Institute, Seoul National University, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0003-3007-8653
Franck BielleSorbonne Université, UMR S 1127, INSERM U 1127, CNRS, ICM-Paris Brain Institute, Equipe Labellisée LNCC, Paris, France.ORCID http://orcid.org/0000-0001-6564-6388
Alice LaurengeAP-HP, Groupe Hospitalier Pitié-Salpêtrière, Neuropathology, Paris, France.ORCID http://orcid.org/0000-0002-0058-3176
Anna Luisa Di StefanoNeurology Department, Foch Hospital, Suresnes, France.
Bertrand MathonAP-HP, Groupe Hospitalier Pitié-Salpêtrière, Neurosurgery, Paris, France.ORCID http://orcid.org/0000-0002-9182-5846
Alberto PiccaSorbonne Université, UMR S 1127, INSERM U 1127, CNRS, ICM-Paris Brain Institute, Equipe Labellisée LNCC, Paris, France.
Marc SansonSorbonne Université, UMR S 1127, INSERM U 1127, CNRS, ICM-Paris Brain Institute, Equipe Labellisée LNCC, Paris, France.
Ann-Christin HauNORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.ORCID http://orcid.org/0000-0002-4412-2355
Frank HertelNORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
Kamil GrzybNORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
Zheng ZhaoBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.ORCID http://orcid.org/0000-0001-8945-9632
Qianghu WangInstitute for Brain Tumors, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.ORCID http://orcid.org/0000-0002-3488-1059
Tao JiangBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Julie J MillerTranslational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Hiroaki WakimotoTranslational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8225-241X
Daniel P CahillTranslational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jennifer MoliternoDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.
Murat GünelDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-2290-7055
Beth HermesSt Joseph's Hospital and Barrow Neurological Institute, Phoenix, AZ, USA.
Nader SanaiSt Joseph's Hospital and Barrow Neurological Institute, Phoenix, AZ, USA.
Anna GolebiewskaNORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.ORCID http://orcid.org/0000-0002-4160-2521
Simone P NiclouNORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.ORCID http://orcid.org/0000-0002-3417-9534
Jason HuseDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
W K Alfred YungDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1669-0793
Anna LasorellaDepartment of Public Health Sciences, Division of Biostatistics, University of Miami, Miller School of Medicine, Miami, FL, USA. axl4252@med.miami.edu.
Mario L SuvàDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. suva.mario@mgh.harvard.edu.ORCID http://orcid.org/0000-0001-9898-5351
Antonio IavaroneSylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA. axi435@med.miami.edu.ORCID http://orcid.org/0000-0002-0683-4634
Itay TiroshDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. Itay.tirosh@weizmann.ac.il.ORCID http://orcid.org/0000-0001-5477-2987
Roel G W VerhaakDepartment of Neurosurgery, Yale School of Medicine, New Haven, CT, USA. roel.verhaak@yale.edu.ORCID http://orcid.org/0000-0003-2773-0436
Funding
Deciphering heritability, plasticity and differentiation trajectories in gliomas via single-cell multi-omicsR01CA258763 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI SUVA, MARIO LUCA · 2021 to 2025
$2.8MNCI NIH HHS R01 CA258763
Abstract
Gliomas with mutant isocitrate dehydrogenase (IDH) are malignant brain tumours that typically arise in early to mid-adulthood and nearly always recur following treatment
Indexed as
Brain NeoplasmsDisease ProgressionGliomaIsocitrate DehydrogenaseMutationAnimalsAstrocytomaCell CycleCell DifferentiationCell LineageCell ProliferationChromatinFemaleGene Expression Regulation, NeoplasticHumansNeoplasm Recurrence, LocalChromatinIsocitrate DehydrogenaseReceptor, Platelet-Derived Growth Factor alpha
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.